A Phase II, Multicenter, Adaptive-design Study to Assess the Safety and Efficacy of VM202RY Injected Via Percutaneous Transendocardial Route in Subjects With Acute Myocardial Infarction
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2018
At a glance
- Drugs Donaperminogene seltoplasmid (Primary)
- Indications Coronary artery disease; Ischaemic heart disorders
- Focus Adverse reactions; Therapeutic Use
- 18 Jan 2018 Status changed from planning to recruiting.
- 02 Aug 2016 According to a VM BioPharma media release, the Ministry of Food and Drug Safety in Korea (MFDS) has approved an Investigational New Drug (IND) application for VM202 for the treatment of ischaemic heart disease facilitating this trial.
- 27 Jan 2016 New trial record